drugset / Trial / NCT00690911

Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis

NCT00690911

Phase 2 Withdrawn Wake Forest University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to see if Humira is effective and safe in the treatment of sarcoidosis.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg Subcutaneous

Indications